SWX:NOVNPharmaceuticals
Novartis Kidney Data And Actinium Deal Shape Long Term Growth Story
Novartis (SWX:NOVN) reported positive final Phase III ALIGN results for Vanrafia in IgA nephropathy, indicating meaningful benefits in kidney function.
The company also signed a long term supply agreement with Niowave for Actinium 225 to support its radioligand therapy portfolio.
For investors watching SWX:NOVN, these updates come against a backdrop of solid recent share performance. The stock closed at CHF125.14 and is up 4.3% over the past week, 7.8% over the past month, 15.3% year to...